Employing a similar strategy, this team constructed a large multiomics cohort of 579 Chinese patients with HR+/HER2– breast cancer, integrating analyses of their somatic copy number alterations, RNA sequencing and metabolome data. This evidence concerns the gene ERBB2 and breast carcinoma.